GSK PLC SP. ADR/2 NEW Total Liabilities
GSK PLC SP. ADR/2 NEW total liabilities. Based on the latest financial reports, GSK PLC SP. ADR/2 NEW (GS70) has total liabilities worth €44.56 Billion EUR (≈ $52.10 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GSK PLC SP. ADR/2 NEW asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GSK PLC SP. ADR/2 NEW (2021–2025)
Total liabilities of GSK PLC SP. ADR/2 NEW from 2021 to 2025. This chart illustrates how GSK PLC SP. ADR/2 NEW's total liabilities have evolved over time, based on quarterly financial data.
GSK PLC SP. ADR/2 NEW Competitors by Total Liabilities
The table below lists competitors of GSK PLC SP. ADR/2 NEW ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pinduoduo Inc
F:9PDA
|
Germany | €214.28 Billion |
|
CME Group Inc
NASDAQ:CME
|
USA | $175.38 Billion |
|
UBS Group AG
SW:UBSG
|
Switzerland | CHF1.53 Trillion |
|
McKesson Corporation
NYSE:MCK
|
USA | $92.19 Billion |
|
Air Liquide SA
PA:AI
|
France | €24.97 Billion |
|
CVS Health Corp
NYSE:CVS
|
USA | $185.68 Billion |
|
Grupo México S.A.B. de C.V
MX:GMEXICOB
|
Mexico | MX$17.34 Billion |
|
General Dynamics Corporation
NYSE:GD
|
USA | $33.34 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down GSK PLC SP. ADR/2 NEW's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of GSK PLC SP. ADR/2 NEW.
Liquidity & Leverage Metrics
GSK PLC SP. ADR/2 NEW Total Liabilities Ratios Explained
GSK PLC SP. ADR/2 NEW total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GSK PLC SP. ADR/2 NEW's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GSK PLC SP. ADR/2 NEW (2021–2025)
The table below shows the annual total liabilities of GSK PLC SP. ADR/2 NEW from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €45.16 Billion ≈ $52.80 Billion |
-2.62% |
| 2024-12-31 | €46.38 Billion ≈ $54.22 Billion |
+0.36% |
| 2023-12-31 | €46.21 Billion ≈ $54.02 Billion |
-7.67% |
| 2022-12-31 | €50.05 Billion ≈ $58.51 Billion |
-13.35% |
| 2021-12-31 | €57.76 Billion ≈ $67.53 Billion |
-- |
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more